Niagen Bioscience, Inc. (filing issuer: ChromaDex Corporation) — 2017 Form 10-K
Reporting period: Fiscal year ended December 30, 2017. This is an annual report, not a standalone fourth-quarter filing; quarterly figures are identified separately below. The company’s business focused on NIAGEN nicotinamide riboside, sold as the TRU NIAGEN consumer supplement, alongside ingredient sales and core standards and contract services.
Financial performance and liquidity
| Metric | 2017 | 2016 |
|---|---|---|
| Net sales | $21.20 million | $21.66 million |
| Gross profit / margin | $10.48 million / 49.4% | $10.39 million / 48.0% |
| Operating loss | $16.38 million | $2.91 million |
| Net loss | $11.38 million | $2.93 million |
| Loss per share, basic and diluted | $0.26 | $0.08 |
| Cash used in operating activities | $9.80 million | $2.94 million |
| Cash and cash equivalents at year-end | $45.39 million | $1.64 million |
| Total assets | $62.72 million | $19.75 million |
| Total liabilities | $8.89 million | $9.78 million |
- Sales fell about 2%. Segment sales were $11.15 million for ingredients (down 34%), $5.46 million for consumer products (launched in 2017), and $4.58 million for core standards and contract services (down 6%).
- Operating expenses rose to $26.85 million from $13.30 million, including sales and marketing of $4.46 million, R&D of $4.01 million, and general and administrative expense of $17.64 million. Higher legal costs, share-based compensation, and consumer-brand investment contributed materially.
- 2017 net loss included a $5.47 million gain on sale of discontinued operations. Excluding that gain, continuing-operations loss was $16.53 million. The filing reports a 2017 operating margin of approximately negative 77% and net margin of approximately negative 54%.
- Fourth-quarter sales were $7.53 million, gross profit $3.83 million, operating loss $8.78 million, and net loss $8.82 million. The quarter included no discontinued-operations income; the prior quarter’s reported profit included a substantial disposal-related gain.
- Cash from financing activities was $48.95 million, primarily from common-stock offerings and option exercises. The company reported no borrowings under its $5 million revolving credit line at year-end. Capital-lease obligations were about $0.51 million; the company also had $2.09 million of operating-lease commitments and $3.57 million of purchase obligations.
- Year-end current assets were $57.18 million and current liabilities $8.09 million. Separately, management-defined working capital (trade receivables plus inventory less accounts payable) was $7.42 million, versus $7.79 million in 2016.
Material changes, outlook, and risks
- The acquisition of Healthspan Research in March 2017 brought TRU NIAGEN in-house and marked a strategic shift toward a global consumer-product company. Ingredients sales declined as the company reduced supply arrangements with resellers; consumer sales partly offset the decrease.
- The company sold its food-related laboratory testing and analytical chemistry assets to Covance in September 2017 for $6.75 million plus $0.75 million held in escrow. It recorded a $5.47 million gain; a potential additional $1 million earnout was not earned.
- Management expected consumer-product sales and gross profit to grow over the next 12 months and planned to continue increasing marketing and R&D investment. It stated that cash and expected operating cash generation would support projected plans through at least March 16, 2019, while noting it might seek additional capital before then. No numerical revenue or earnings guidance was provided.
- TRU NIAGEN launched in Hong Kong and Macau in 2017 and Singapore in early 2018. Further expansion depends on regulatory approvals and distribution partners. One related-party customer, Customer G, accounted for 19.4% of 2017 sales and approximately $1.0 million of year-end receivables; two customers together represented about 30% of sales.
- Litigation with Elysium remained active across California and New York, alongside patent review proceedings. ChromaDex reported that Elysium had not purchased since August 2016 and owed approximately $2.7 million on prior purchase orders; the company could not estimate a possible loss range. It wrote off approximately $746,000 of royalty receivables in 2017. The PTAB denied review of one patent and instituted review of specified claims of another.
- Other key risks include continued operating losses and cash burn, reliance on NIAGEN/TRU NIAGEN acceptance, customer and supplier concentration, regulatory and product-liability exposure, competition, potential dilution, and uncertainty over patent rights. The company reported effective disclosure controls and internal control over financial reporting; its auditor issued unqualified opinions.
Important facts for investors to verify
- Whether consumer-product growth and gross profit can compensate for declining ingredient sales and rising marketing and R&D costs.
- Current cash runway and cash burn relative to management’s stated March 2019 funding horizon, including subsequent financing needs and dilution.
- Developments in Elysium litigation, collectability of disputed receivables, and the outcome of patent review proceedings.
- Customer G’s continuing contribution, related-party terms, and collection of its receivable; also monitor broader customer concentration.
- Progress on international regulatory approvals, distribution launches, and clinical research supporting NIAGEN claims.
- Reconciliation of reported annual and quarterly results, particularly the disposal gain and discontinued operations; the filing’s fiscal 2017 fourth-quarter operating loss was materially higher than earlier quarters.